372 related articles for article (PubMed ID: 32998746)
21. Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy.
Killu AM; Park JY; Sara JD; Hodge DO; Gersh BJ; Nishimura RA; Asirvatham SJ; McLeod CJ
Europace; 2018 Jan; 20(1):82-88. PubMed ID: 29315424
[TBL] [Abstract][Full Text] [Related]
22. Functional effects of glucose transporters in human ventricular myocardium.
von Lewinski D; Gasser R; Rainer PP; Huber MS; Wilhelm B; Roessl U; Haas T; Wasler A; Grimm M; Bisping E; Pieske B
Eur J Heart Fail; 2010 Feb; 12(2):106-13. PubMed ID: 20083620
[TBL] [Abstract][Full Text] [Related]
23. Effects of surgical ventricular reconstruction and mitral complex reconstruction on cardiac oxidative metabolism and efficiency in nonischemic and ischemic dilated cardiomyopathy.
Sugiki T; Naya M; Manabe O; Wakasa S; Kubota S; Chiba S; Iwano H; Yamada S; Yoshinaga K; Tamaki N; Tsutsui H; Matsui Y
JACC Cardiovasc Imaging; 2011 Jul; 4(7):762-70. PubMed ID: 21757167
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.
Sawa Y; Saito M; Ishida N; Ibi M; Matsushita N; Morino Y; Taira E; Hirose M
J Pharmacol Sci; 2020 Jan; 142(1):16-25. PubMed ID: 31776072
[TBL] [Abstract][Full Text] [Related]
25. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
Pitt B; Steg G; Leiter LA; Bhatt DL
Cardiovasc Drugs Ther; 2022 Jun; 36(3):561-567. PubMed ID: 34750713
[TBL] [Abstract][Full Text] [Related]
26. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function.
Shi FH; Li H; Shen L; Xu L; Ge H; Gu ZC; Lin HW; Pu J
J Clin Endocrinol Metab; 2022 Mar; 107(4):1191-1203. PubMed ID: 34791312
[TBL] [Abstract][Full Text] [Related]
27. Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances.
Stellbrink C; Breithardt OA; Franke A; Sack S; Bakker P; Auricchio A; Pochet T; Salo R; Kramer A; Spinelli J;
J Am Coll Cardiol; 2001 Dec; 38(7):1957-65. PubMed ID: 11738300
[TBL] [Abstract][Full Text] [Related]
28. The ischemic etiology of heart failure in diabetics limits reverse left ventricular remodeling after cardiac resynchronization therapy.
Soliman OI; van Dalen BM; Theuns DA; ten Cate FJ; Nemes A; Jordaens LJ; Geleijnse ML
J Diabetes Complications; 2009; 23(5):365-70. PubMed ID: 18572420
[TBL] [Abstract][Full Text] [Related]
29. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial.
St John Sutton M; Linde C; Gold MR; Abraham WT; Ghio S; Cerkvenik J; Daubert JC;
JACC Heart Fail; 2017 Mar; 5(3):169-178. PubMed ID: 28254122
[TBL] [Abstract][Full Text] [Related]
30. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
31. Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure.
Wang J; Gong X; Chen H; Qin S; Zhou N; Su Y; Ge J
J Cardiovasc Electrophysiol; 2017 Apr; 28(4):438-445. PubMed ID: 28127817
[TBL] [Abstract][Full Text] [Related]
32. Right ventricular myocardial function in patients with either idiopathic or ischemic dilated cardiomyopathy without clinical sign of right heart failure: effects of cardiac resynchronization therapy.
D'Andrea A; Salerno G; Scarafile R; Riegler L; Gravino R; Castaldo F; Cocchia R; Limongelli G; Romano M; Calabrò P; Nigro G; Cuomo S; Bossone E; Caso P; Calabrò R
Pacing Clin Electrophysiol; 2009 Aug; 32(8):1017-29. PubMed ID: 19659622
[TBL] [Abstract][Full Text] [Related]
33. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Dominguez Rieg JA; Rieg T
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
[TBL] [Abstract][Full Text] [Related]
34. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
35. Chronic heart failure selectively induces regional heterogeneity of insulin-responsive glucose transporters.
Ware B; Bevier M; Nishijima Y; Rogers S; Carnes CA; Lacombe VA
Am J Physiol Regul Integr Comp Physiol; 2011 Nov; 301(5):R1300-6. PubMed ID: 21849635
[TBL] [Abstract][Full Text] [Related]
36. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes.
Sardu C; Barbieri M; Santamaria M; Giordano V; Sacra C; Paolisso P; Spirito A; Marfella R; Paolisso G; Rizzo MR
Cardiovasc Diabetol; 2017 Jun; 16(1):75. PubMed ID: 28599667
[TBL] [Abstract][Full Text] [Related]
37. Expression of glucose transporters in human peritoneal mesothelial cells.
Schröppel B; Fischereder M; Wiese P; Segerer S; Huber S; Kretzler M; Heiss P; Sitter T; Schlöndorff D
Kidney Int; 1998 May; 53(5):1278-87. PubMed ID: 9573543
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.
Schipper ME; Scheenstra MR; van Kuik J; van Wichen DF; van der Weide P; Dullens HF; Lahpor J; de Jonge N; De Weger RA
J Heart Lung Transplant; 2011 Jul; 30(7):805-10. PubMed ID: 21531579
[TBL] [Abstract][Full Text] [Related]
39. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
40. Effects of canagliflozin on human myocardial redox signalling: clinical implications.
Kondo H; Akoumianakis I; Badi I; Akawi N; Kotanidis CP; Polkinghorne M; Stadiotti I; Sommariva E; Antonopoulos AS; Carena MC; Oikonomou EK; Reus EM; Sayeed R; Krasopoulos G; Srivastava V; Farid S; Chuaiphichai S; Shirodaria C; Channon KM; Casadei B; Antoniades C
Eur Heart J; 2021 Dec; 42(48):4947-4960. PubMed ID: 34293101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
